Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are currently recommended as first-line treatment for advanced non-small-cell lung cancer (NSCLC) with EGFR-activating mutations. Third-generation (3rd G) EGFR-TKIs, including osimertinib, offer an effective treatment option f...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahfoudhi, Emna, Ricordel, Charles, Lecuyer, Gwendoline, Mouric, Cécile, Lena, Hervé, Pedeux, Rémy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023070/
https://www.ncbi.nlm.nih.gov/pubmed/35463360
http://dx.doi.org/10.3389/fonc.2022.853501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023070/
https://www.ncbi.nlm.nih.gov/pubmed/35463360
http://dx.doi.org/10.3389/fonc.2022.853501

Ejemplares similares